ESMO 2021: KEYNOTE-676 Cohort B: Randomized Comparator-Controlled Cohort To Evaluate Efficacy and Safety of Pembrolizumab Plus BCG in Patients With High-Risk BCG Treatment-Naive NMIBC

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Shahrokh Shariat presented the KEYNOTE-676 Cohort B trial in progress.